Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30...
News
Agomab outlines design of phase 2b NOV‑ERA study in fibrostenosing Crohn’s disease
FDA alignment secured as company prepares to begin dosing in 2026
Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC
Breakwater phase 3 data show significant gains in progression‑free survival
Cenrifki approved in EU for secondary progressive multiple sclerosis
Sanofi therapy becomes first disability‑targeting medicine for nrSPMS
NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
Final draft guidance recommends D‑VRd on the NHS in England and Wales
Anocca doses first patients with precision TCR‑T therapy
Company begins phase 1 treatment in multi‑centre VIDAR‑1 trial
Connecta launches phase 2a trial of neuroplasticity modulator
Study marks major milestone for CTH120 as company advances disease‑modifying ambitions
Aquipta recommended by NICE for acute migraine treatment
Guidance paves the way for NHS access for eligible adults in England and Wales
Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments
Alzecure enters collaboration and with Lilly for Alzheimer’s project
Partnership grants Lilly global rights to Alzstatin ACD680
Survodutide trial data show targeted visceral and liver fat reductions
Phase 3 results highlight metabolic benefits alongside weight loss
Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
Late‑breaking EULAR results highlight sustained responses through week 52
European approval enables measles protection with CSL’s immunoglobulin Privigen
Commission authorisation expands access to passive measles prophylaxis for vulnerable patients
JJP Biologics reports positive interim phase 1b data for nebaprubart
Early clinical activity supports expansion into broader IgA‑mediated conditions
Immunotherapy boost can spare more bladder cancer patients major surgery
Adding durvalumab to chemoradiation helps people avoid having their bladder removed
